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Background: The use of equine bone marrow mesenchymal stem cells (BMSC) is a novel method to improve
fracture healing in horses. However, additional research is needed to identify optimal culture conditions and to
determine the mechanisms involved in regulating BMSC differentiation into osteoblasts. The objectives of the
experiments were to determine: 1) if autologous or commercial serum is better for proliferation and differentiation
of equine BMSC into osteoblasts, and 2) the expression of key transcription factors during the differentiation of
equine BMSC into osteoblasts. Equine BMSC were isolated from the sterna of 3 horses, treated with purchased fetal
bovine serum (FBS) or autologous horse serum (HS), and cell proliferation determined. To induce osteoblast
differentiation, cells were incubated with L-ascorbic acid-2-phosphate and glycerol-2-phosphate in the presence or absence
of human bone morphogenetic protein2 (BMP2), dexamethasone (DEX), or combination of the two. Alkaline phosphatase
(ALP) activity, a marker of osteoblast differentiation, was determined by ELISA. Total RNA was isolated from differentiating
BMSC between d 0 to 18 to determine expression of runt-related transcription factor2 (Runx2), osterix (Osx), and T-box3
(Tbx3). Data were analyzed by ANOVA.
Results: Relative to control, FBS and HS increased cell number (133 ± 5 and 116 ± 5%, respectively; P< 0.001) and 5-bromo-
2'-deoxyuridine (BrdU) incorporation (167 ± 6 and 120 ± 6%, respectively; P< 0.001). Treatment with DEX increased ALP
activity compared with control (1,638 ± 38%; P < 0.001). In the absence and presence of Dex, BMP-2 did not alter
ALP activity (P > 0.8). Runt-related transcription factor2 expression increased 3-fold (P < 0.001) by d 6 of culture.
Osterix expression increased 9-fold (P < 0.05) by d 18 of culture. Expression of Tbx3 increased 1.8-fold at d 3 (P < 0.01);
however expression was reduced 4-fold at d 18 (P < 0.01).
Conclusions: Dexamethasone, but not BMP-2, is required for differentiation of equine BMSC into osteoblasts. In
addition, expression of Runx2 and osterix increased and expression of Tbx3 is reduced during differentiation.
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Equine bone fractures are often catastrophic and poten-
tially fatal, as well as costly to owners [1]. It is estimated
that annual losses due to bone fractures in the horse-
racing industry exceed $10 million [2]. To repair a frac-
ture, costs vary greatly between $2,000 and $10,000 per
surgery [3]. This does not include the post-surgical care
and rehabilitation which can cost between $100 and
$2,000 per d for the first 3 to 4 wk after the surgery
[4,5]. Traditional methods of healing fractures have lim-
ited success, leading to the need for additional research
to identify more successful and economical ways of heal-
ing fractured bone [6,7]. Recent advancements include
the use of adult stem cells, specifically, bone marrow
mesenchymal stem cells (BMSC), in fracture healing [8].
However, the methods for isolation and culture of these
cells, and mechanisms regulating BMSC differentiation
into osteoblasts (bone forming cells) are not well estab-
lished in the equine model. Research utilizing rodent or
human models has demonstrated that BMSC have the
ability to improve bone healing while reducing the risk
of re-fracture [9,10] and that addition of certain factors
[i.e., fibroblast growth factor, bone morphogenic protein
(BMP)] improve fracture healing. Before the findings in
humans and rodents can be translated to horses, it must
be determined if equine BMSC function similar in cul-
ture and if similar mechanisms are involved in regulating
the differentiation of BMSC into osteoblasts.
Several studies have attempted to determine the opti-
mal culture conditions for BMSC in various species
since expansion of these cells is often needed before re-
introduction to the fracture site. The source of serum
can affect cell function; however the effects of autolo-
gous vs. commercially available serum are variable. Spe-
cifically, in rats, BMSC grown in autologous serum had
greater growth rates and larger colony sizes than BMSC
grown in fetal bovine serum (FBS) [11]. In human
BMSC, it was determined that FBS vs. autologous serum
did not affect cell number doubling or deoxyribonucleic
acid (DNA) copy number [12]. In the equine model,
there is evidence that BMSC grow slower in autologous
serum compared with FBS [13], but results are often
variable depending on the study conditions and objec-
tives. Based on the discrepancy between experiments
and species, further experiments are needed to deter-
mine the source of serum for culturing BMSC for use ei-
ther as therapeutic agents or for in vitro experiments.
Through human and rodent models we know that the
differentiation of BMSC into osteoblasts is a complex
process that is regulated by a number of transcription
factors. In particular, there are two master genes, runt-
related transcription factor 2 (Runx2; required for early
differentiation) and osterix (Osx; required for later dif-
ferentiation), required for osteoblast differentiation andmineralization [14]. Characterization of these transcrip-
tion factors and effects of certain agents (dexamethasone,
BMP) on differentiation of BMSC into osteoblasts are not
well known in the equine model. Another transcription
factor recently identified to have a role in osteoblast differ-
entiation is T-box3 (Tbx3). Over-expression of Tbx3 in-
hibits osteoblast differentiation and the expression of
Runx2 and Osx in mouse osteoblasts [15]; however, the
expression of Tbx3 has not been characterized in the
horse. Therefore, the objectives of the current research
were to determine: 1) if autologous or commercial serum
is better for proliferation and differentiation of equine
BMSC into osteoblasts, and 2) the expression of key tran-
scription factors (Runx2, Osx, Tbx3) during the differenti-
ation of equine BMSC into osteoblasts.
Material and methods
Before the start of the experiments protocols were ap-
proved by the Institutional Animal Care and Use Com-
mittee at the University of Connecticut.
Animals
Morgan horses (N = 3; 1 male, 2 females) between 3 and
5 yr of age from the University of Connecticut herd were
used. A complete physical examination of the animals
was conducted by a veterinarian before procedures.
Serum collection for cell culture
Serum (HS) was collected from each animal one wk be-
fore BMSC isolation. Animals were sedated with detomi-
dine hydrochloride (0.02 mg/kg btw) intravenously.
Approximately 500 mL of blood was taken and and
stored in 50 mL tubes. Blood was incubated at room
temperature for 2 to 4 h to allow clotting. The blood
was refrigerated at 4°C for 10 to 12 h. Next, the tubes
were centrifuged at 1,800 × g for 30 min at 4°C. In a
sterile environment, the serum was transferred by gently
pipetting into a new tube. The serum was filtered through
0.22 μm pores. Next, the serum was frozen at −20°C for
12 h. The next d, the serum was thawed to room
temperature, heat inactivated by incubating at 56°C for
30 min, filtered through 0.22 μm pores, and stored at 4°C
for immediate use or −20°C for future use in cell culture
experiments [13].
Bone marrow aspiration
Approximately 1.5 mL of 2% lidocaine were used to infil-
trate the subcutaneous area directly above a jugular vein.
A 14 gauge, 6 inch catheter was inserted and the horse
was sedated with detomidine hydrochloride (0.02 mg/kg
body weight) and butorphanol tartrate (0.1 mg/kg body
weight). The area of the sternum was clipped and pre-
pared aseptically. Approximately 8 mL of 2% lidocaine
was infiltrated into the subcutaneous tissue, muscle, and
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(Jorgensen Laboratories, Loveland, CO, USA) was in-
troduced through a stab incision, made in the soft tis-
sue area of the sternum, and advanced through the
muscle layers until it made contact with the ventral
surface of the sternum [16]. Pressure was applied to
advance the needle until it was seated 1 to 2 cm into
the bone. A total of 5 to 15 mL of bone marrow were
obtained from each horse using a 20 mL syringe con-
taining 5 mL heparin. The incision was closed with
one to two surgical staples. Following bone marrow aspir-
ation, horses received flunixin meglumine (1.1 mg/kg
body weight) daily intravenously, twice for the first 3 d
and then once daily for d 4 through 6. Staples were re-
moved 14 d after procedure and no negative effects of the
procedures were observed in donor horses.
Culture of BMSC
The bone marrow was placed on ice, transported to the
laboratory (approximately 1 km), transferred to a 25 mL
canonical tube, and centrifuged at 1,000 × g (3 min; room
temperature). The supernatant was removed and pellet
re-suspended in 10 mL α-minimum essential medium
(MEM; Life Technologies, Grand Island, NY, USA) and
40 mL ammonium chloride (Stemcell technologies,
Vancouver, BC, Canada) to lyse red blood cells. The
sample was vortexed, placed on ice for 10 min, and
re-centrifuged at 1,000 × g (3 min; room temperature).
The supernatant was removed, cells were resuspended in
10 mL α-MEM, and vortexed. The sample was filtered
(70 μm cell strainer), reconstituted in maintenance media
(Table 1), and plated in a 100 mm cell culture dish (1 per
2 mL of bone marrow). In preliminary experiments with
these cells, we determined that some cells attached
quickly (within 1 h) and other cells took 3 to 7 d to adhere
to the culture dish. To determine if there was a difference
in the ability of these cells to proliferate, cells were sepa-
rated for initial proliferation experiments. The cells were
incubated at 37°C, 5% CO2 for 20 min to establish the
early adherence cell population. Six milliliters of main-
tenance media were added to adherent cells. Non-Table 1 Cell culture media1
Media type Composition of media
Maintenance media α-MEM + 10% FBS + 1% PS + 1% AB
Proliferation media α-MEM + 0.1% BSA + 1% PS + 1% AB
ALP media α-MEM + 0.1% BSA + 1% PS + 1% AB +
VC + BG
Differentiation media α-MEM + 10% FBS + 1% PS + 1% AB +
VC + BG + DEX
1ALP = alkaline phosphatase; AB = amphotericin B; α-MEM= α-minimum essential
medium; BSA = bovine serum albumin; BG = glycerol 2-phosphate disodium
salt hydrate; DEX = dexamethasone; FBS = fetal bovine serum; PS = penicillin/
streptomycin concentrate; VC = L-ascorbic acid 2-phosphate
sesquimagnesium salt.adherent cells were removed, counted and re-plated at 6
or 12 million cells/plate in maintenance media to establish
the late adherent population. All cells were maintained at
37°C, 5% CO2 for 3 d and then 4 mL fresh maintenance
media added. After 6 d, media and any remaining non-
adherent cells were removed, and cells washed with PBS
and media replaced every 3 d until cells reached 70% con-
fluence. All experiments were repeated two to four times
using cells from each of the three animals at the fourth
passage. Results were consistent across animals and
replicates.
Cell proliferation
Cell proliferation was determined by alamarBlue and
5-bromo-2'-deoxyuridine (BrdU) assays [15]. Cells were
passed and plated in a 96-well plate (3,000 cells/100 μL
maintenance media/well; n = 8 wells/treatment) and
allowed to adhere for 48 h. Cells were serum deprived
for 24 h and treated with or without 5% FBS (Stemcell
technologies) or 5% HS for 48 h. For alamarBlue as-
says, cells were rinsed twice (PBS), and a 1:10 dilution
of alamarBlue indicator (Life Technologies): α-MEM
at 100 μL/well was added. Plates were incubated for
4 h at 37°C, 5% CO2 and fluorescence was detected
(Synergy2; Biotek, Winooski, VT, USA) at 540/35 ×
600/40 nm with sensitivity at 54. For the BrdUrd assay,
the Cell Proliferation ELISA BrdUrd (chemiluminescent)
Kit (Roche Diagnostics, Indianapolis, IN, USA) was used
according to the manufacturer’s protocol.
Cell differentiation
To determine the ideal reagents to use to stimulate
osteoblast differentiation, alkaline phosphatase (ALP) en-
zyme activity was determined as an endpoint [17]. This is
a well-established early marker of osteoblast differenti-
ation in in vitro experiments. Cells were passed and plated
in a 96-well plate (6,000 cells/100 μL maintenance media/
well; n = 8 wells/treatment). After 48 h, cells were rinsed
twice and re-plated in serum-free ALP media (Table 1).
After 24 h, cells were treated in the absence or presence of
human BMP-2 (30 or 60 ng/mL; PeproTech, Rocky Hill,
NJ, USA), dexamethasone (DEX; 25 mg/mL; Sigma
Aldrich, St. Louis, MO, USA), or the combination of
the two [18]. After 72 h, ALP activity was determined
as previously described [19] and standardized to pro-
tein (Quick Start Bradford Protein; Bio-Rad, Hercules,
CA, USA). Specifically, cells were washed twice with
PBS and permealized with 100 μL of 0.1% triton,
followed by a freeze and thaw. Of the total 100 μL,
40 μL and 20 μL of the lysate were transferred to two
new 96-well plates for determination the ALP activity and
protein concentration, respectively. To determine ALP activ-
ity, 200 μL of the ALP substrate, p-Nitrophenyl phosphate
(Sigma), were added to each well. The absorbance was read




ALP (Forward) GACATGACCTCCCAGGAAGA XM_001504312.1
ALP (Reverse) GCAGTGAAGGGCTTCTTGTC
GAPDH (Forward) ATCACTGCCACCCAGAAGAC NM_001163856
GAPDH (Reverse) GTGAGCTTCCCATTCAGCTC
Osteocalcin (Forward) GTGCAGAGTCTGGCAGAGGT XM_001915727.1
Osteocalcin (Reverse) CCAGCCAATGATCCAGGTAG
Osterix (Forward) GCTCACTATGGCTCCAGTCC XM_001494930.3
Osterix (Reverse) AAGGTCACTGCCCACAGAGT








T-box3 (Forward) GCATCCCTTTCTCGTCTCTG XM_001914978
T-box3 (Reverse) GACCATCTCGGTACCCCTCT
1ALP = alkaline phosphatase; GAPDH = glyceraldehyde 3-phosphate
dehydrogenase.
Runx2 = runt-related transcription factor 2.
2All sequences from NCBI.
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mately 2 h after substrate addition at 405 nm using the plate
reader (Synergy 2; Biotek). The protein concentration was
determined by measuring the absorbance following treat-
ment with Quick Start Bradford Protein (Bio-Rad). The pro-
tein concentration was standardized with serial dilutions of
bovine serum albumin (BSA; Sigma Aldrich). The ALP
activity was standardized to the cellular protein content.
To determine the expression of key markers of osteo-
blast differentiation and transcription factors involved in
regulating osteoblast differentiation, we cultured cells in
differentiation medium for 18 d. Based on our findings
that DEX, but not BMP-2, stimulated ALP activity, we
used DEX for our gene expression experiments. Equine
BMSC were plated in 6-well plates (150,000 cells/plate/
2 mL maintenance media). At 90% confluence, the media
were changed to differentiation media (d 0; Table 1), new
media were replaced every 3 d, and cells were stained on d
0 and 18 with Alizarin Red and ALP to confirm osteoblast
differentiation during the 18 d of culture as previously de-
scribed [15,19]. Briefly, for Alizarin Red Staining (Sigma
Aldrich), media were removed, and then cells were fixed
with cold methanol and frozen at −20°C (12 h). Cells were
then stained with Alizarin Red, and incubated on a rotator
(10 min; room temperature; 100 rpm). Stain was removed
and plates were air-dried. For ALP staining, media were
removed and cells fixed in cold 100% methanol (20 min;
room temperature). Methanol was removed, substrate-
diazonium solution added and cells were incubated
(30 min; 37°C). Then stain was removed and plates
were stored (4°C). Photographs of each well were taken
(Olympus IX70; Olympus, Center Valley, PA, USA), and
ALP and Alizarin Red stains were quantified from each
photograph by determining the amount of stain incorpo-
rated using ImageJ software. Data are expressed as a per-
centage of cells stained on d 0.
Gene expression analysis
As described in the previous section, cells were plated in
6-well plates (150,000 cells/well) and at 90% confluence,
media were changed to differentiation media (d 0), for 18
d and RNA was extracted every 3 d [20] utilizing TriRea-
gent (Sigma) and RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) according to the manufacturer’s protocol. Contam-
inating DNA was removed (TURBO DNA-free kit; Life
Technologies), RNA quality determined (Experion RNA
StdSens Analysis; Bio-Rad) and concentration determined
(NanoDrop spectrophotometer; Fisher Scientific, Pittsburgh,
PA, USA).
Gene expression was determined by real-time reverse
transcriptase (RT)-PCR as previously described [20] using
Superscript II (Invitrogen, Grand Island, NY, USA) and
7900HT Fast Real-Time PCR system (Life Technologies).
Each reaction contained 10 μL of 2X Power SYBR GreenMaster Mix (Life Technologies), 1 μL of 10 mmol/L of for-
ward and reverse primer (Table 2), 3 μL of nuclease free
water, and 5 μL of cDNA. Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) was used as an endogenous con-
trol. DeltaCT values were determined and comparisons of
the deltaCT values were used for relative quantification
[21]. Expression of osteocalcin (Oc) and ALP, key markers
of osteoblast differentiation, were determined to confirm
differentiation into osteoblasts (Table 2).
Statistical analysis
Data were analyzed using the PROC-MIXED procedure
of the statistical analysis software (SAS Inst. Inc, Cary,
NC, USA) with animal within treatment as the random
statement. Suitable corrections were made for multiple
comparisons. Differences between means were deter-
mined using LSMEANS where appropriate. Data are
presented as mean ± SEM with significant difference at
P ≤ 0.05.
Results
Conditions for proliferating equine BMSC
To determine if BMSC that adhere early (within 20 min)
or late (within 6 d) differ in their proliferation rate, we
determined cell number and BrdU incorporation. In the
absence and presence of serum (FBS), we did not ob-
serve a difference in proliferation of cells between early
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BrdU incorporation (Figure 1). In both cell populations
FBS increased cell proliferation compared with serum-
free media (BSA; P < 0.0001) as demonstrated by BrdU
incorporation (Figure 1). Similarly, in the alamarBlue
assay, FBS stimulated cell proliferation in both early and
late adherent cells, but we did not detect a difference in
their response to FBS (134 ± 5 vs. 133 ± 5% of control for
early and late, respectively; P > 0.20).
To determine if autologous serum provided a better
environment for proliferation than commercially avail-
able FBS, cells were cultured in the presence or absence
of HS or FBS. Both HS and FBS significantly increased
BrdU incorporation (Figure 2; P < 0.05); however cells
treated with FBS had a greater increase in BrdU incorp-
oration (Figure 2) than cells treated with HS (P < 0.02).
Similar findings were observed with alamarBlue assay
(116 ± 5 vs. 133 ± 5% compared with control for HS vs.
FBS, respectively; P = 0.01). Based on these data, we used
the late adherent cells with FBS supplement for the
remaining experiments.
Effects of BMP-2 and DEX on differentiation of BMSC into
osteoblasts
Cells were treated with human BMP-2 and DEX, known
stimulators of differentiation of BMSC into osteoblasts.
Dexamethasone increased ALP activity 6-fold (P < 0.0001;
Figure 3). In both the absence and presence of DEX,
BMP-2 did not alter ALP activity (No Dex: 150 ± 88,
143 ± 81, and 160 ± 81 mU/mg for 0, 30, and 60 ng/mL



























Figure 1 Proliferation is similar between early and late adherence eq
[bovine serum albumin (BSA)] or presence (BSA + fetal bovine serum) of se
deoxyuridine (BrdU) assays. Data presented are from the BrdU assay and sim
as mean ± SEM. Bars with different letters are significantly different (P < 0.0576 mU/mg for 0, 30, and 60 ng/mL hBMP-2; P > 0.8;
Figure 3).
Gene expression during differentiation of BMSC into
osteoblasts
By d 18 of culture a 4-fold increase in Alizarin Red stain
was observed compared with d 0 (P < 0.05; Figure 4A),
demonstrating successful differentiation into osteoblasts.
Consistent with these findings, a 50% increase in ALP
staining was observed between d 0 and 18 (P < 0.05).
During differentiation, ALP mRNA expression increased
by d 6 and remained elevated, although variable, through
d 18 of culture compared with d 0 (P < 0.001; Figure 4B).
In addition, osteocalcin expression increased over 200-
fold by d 18 of culture compared with d 0 (P ≤ 0.05;
Figure 4B), thus confirming the differentiation of BMSC
into osteoblasts.
Runt-related transcription factor 2 expression increased
3-fold on d 6 and remained increased through d 18 of cul-
ture compared with d 0 (P < 0.01; Figure 4C). Osterix ex-
pression increased as early as d 6 and by 9-fold at d 18
compared with d 0 (P < 0.05; Figure 4C). In addition, ex-
pression of Tbx3, increased 1.8-fold at d 3 (P = 0.05), but
then decreased more than 4-fold by d 15 of culture com-
pared with d 0 (P < 0.05; Figure 4C).
Discussion
Similar to previous work using equine BMSC in culture,
equine BMSC were isolated and able to proliferate and
differentiate using standard culture media and serum




uine bone marrow stromal cells. Cells were cultured in the absence
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Figure 2 Cell proliferation is greater in the presence of fetal bovine serum (FBS) compared with horse serum (HS). Equine bone marrow
stromal cells were treated with 5% HS or 5% FBS and cell proliferation was determined by alamarBlue and 5-bromo-2'-deoxyuridine (BrdU) assays.
Data are presented from the BrdU assay and similar findings were observed with the alamarBlue assay. Data are presented as mean ± SEM and
expressed as a % of control. *indicates a significant difference between the two treatments at P < 0.02.
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lations of cells that adhere to the plastic culture dish at
different rates. A recent publication demonstrated that
these two populations differ in adherence rate, but still
retained their capacity to differentiate along the osteogenic
lineage [24], therefore we further evaluated the ability of
these cells to attach and proliferate in our culture system.
The current findings demonstrate that these two popula-





















Figure 3 Dexamethasone (DEX) increases alkaline phosphatase (ALP)
the absence (Control) or presence of DEX and bone morphogenic protein
enzyme activity. Data are presented as mean ± SEM. *indicates a significantis similar to findings in a human model [24]. Based on the
findings that BMSC from both early and late populations
had a similar proliferative rate, it was concluded that ei-
ther population of cells could be used for additional exper-
iments, and future experiments should consider using a
combination of the two populations.
The use of autologous serum for reintroduction of
stem cells is advantageous to reduce rate of rejection.




activity in equine bone marrow stem cells. Cells were cultured in
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Figure 4 (See legend on next page.)
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Figure 4 Expression of key transcription factors during differentiation of equine bone marrow stem cells into osteoblasts. Equine bone
marrow stromal cells were treated with differentiation media for 18 d. A. Cells were stained with Alizarin Red on d 0 (DO) and 18 (D18).
Quantification of mineralization is presented as mean ± SEM. *indicates a significant difference between d 0 and 18 (P < 0.05). Real-time reverse
transcription PCR was performed on samples every 3 d (n = 6 wells/d) to determine expression of: B. markers of osteoblast differentiation
[osteocalcin (OC) and alkaline phosphatase (ALP)] and C. key transcription factors [osterix (Osx), runt-related transcription factor 2 (Runx2) and
T-box3 (Tbx3)]. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the endogenous control. Data are presented as fold change
from d 0 (mean ± SEM). *indicates that a significant difference in mRNA expression from d 0 was observed for all genes on all d, except for
Tbx3 expression on d 6 (P < 0.05).
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are not clear. Based on conflicting reports in rodent and
equine models [11,13], the effects of HS vs. FBS on cell
proliferation were determined. The findings that FBS
had a greater stimulatory effect on cell proliferation than
autologous serum are consistent with previous reports
in the equine model [13], but are in contrast to findings
in a rat model [11]. The differences observed between
HS and FBS may be due to the older age of the horses
from which serum was collected compared with the
young age of the cattle used for commercial serum col-
lection. In addition, commercially produced FBS may
contain less factors (i.e., bacteria) that could inhibit pro-
liferation than the autologous HS due to the various
steps used to purify commercial serum vs. the basic fil-
tration protocols used in most research laboratories for
autologous serum. Based on the consistent findings in
the current and previous research, it was concluded that
for in vitro experiments, BMSC should be cultured in
FBS for optimal in vitro proliferation which is critical for
rapid development of a pool of BMSC. In addition, the
use of FBS is advantageous because FBS is a commer-
cially available product of good quality which will pro-
vide more consistency in research performed in different
laboratories. It should be noted that proliferation experi-
ments were for a short duration (48 h) and additional ex-
periments are needed to determine if similar effects are
observed when cells are cultured for several wk or multiple
passages. We did observe during our experiments that cells
were able to be passed several times (10 or more) without
noticeable differences in cell proliferation or viability.
To determine the expression of key transcription fac-
tors known to regulate differentiation of BMSC into os-
teoblasts, the first step was to determine factors that
would stimulate osteoblast differentiation, such as dexa-
methasone and BMP [25,26]. Consistent with findings in
rodents and humans [27], DEX increased the differenti-
ation of BMSC into osteoblasts. An effect of BMP-2 on
the differentiation of BMSC into osteoblasts was not ob-
served which is in contrast to a recent report in the
equine model in which BMP-2 stimulated differentiation
of BMSC [19]. Carpenter et al. used a retroviral vector
to introduce human BMP-2 [19], whereas we added it
directly to the media at one time point. These findingssuggest that the method of addition of BMP-2, dose, and
duration of treatment may have an impact on the effi-
cacy of BMP-2 treatment. Further studies are needed to
determine if continuous treatment with BMP-2, as seen
with transduction of the gene, is more effective than a
single dose in culture.
Similar to previous reports in rodents and humans expres-
sion of ALP and osteocalcin increased during the differenti-
ation of equine BMSC into osteoblasts [15,28]. Alkaline
phosphatase, an early marker of osteoblast differentiation,
rapidly increased by d 3 and 6, whereas expression was vari-
able at later time points. It is not clear what contributed to
the variation, but important to note that expression
remained elevated while expression of osteocalcin, a later
marker of differentiation, continued to increase greatly
through d 18. These findings confirm the effectiveness of
the differentiation media and that equine BMSC can be in-
duced to differentiate along the osteoblast lineage in culture.
Expression of key master regulatory transcription fac-
tors, Runx2 and Osx, was similar to rodents and
humans, such that expression of Runx2 was greatest
during the first 6 d of differentiation and Osx expression
was greatest at the final d of culture [28]. These findings
suggest that similar to other species, Runx2 and Osx may
be critical for optimal bone formation, mineralization and
osteoblast function in horses [29]. The methods used in
the current study to induce differentiation of BMSC into
osteoblasts were successful and equine osteoblast differen-
tiation may be regulated similarly to osteoblast differenti-
ation in other species. Further studies are needed using
knockdown of these transcription factors to determine
their specific roles in osteogenesis in the equine model.
Since Runx2 and Osx are known to be expressed during
early and late differentiation, respectively [29], the current
findings will be helpful in future studies that aim to deter-
mine the effectiveness of specific factors in inducing the
differentiation of equine BMSC into osteoblasts in vitro.
In the mouse, Tbx3 was recently identified as an im-
portant stimulator of osteoblast proliferation and inhibi-
tor of differentiation, as well as responsive to growth
hormone [15,20]. We provide evidence that Tbx3 is
expressed in equine BMSC and its expression changes
with differentiation along the osteoblast lineage. The re-
duction in Tbx3 expression as BMSC differentiate into
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which over-expression of Tbx3 represses differentiation
of BMSC into osteoblasts [15]. These findings suggest
that Tbx3 may need to be suppressed for optimal dif-
ferentiation. More importantly, in addition to demon-
strating that expression of key transcription factors
during osteoblast differentiation in horses are similar
to human and rodent models, these experiments pro-
vide novel data that Tbx3 expression decreased during
differentiation.Conclusions
In conclusion, the results of the current study demon-
strate greater proliferation of equine BMSC using a com-
mercially available serum and that expression of Runx2
and Osx during differentiation is similar to those re-
ported in other species. In addition, we provide the first
evidence that Tbx3 is expressed in equine cells and ex-
pression is reduced during differentiation, suggesting a
potential inhibitory role in differentiation. Overall, these
findings broaden our knowledge of culture conditions
for equine BMSC and expression of key regulatory fac-
tors during differentiation. These findings will help to
improve culture conditions of equine BMSC for future
experiments that aim to utilize these cells for fracture
healing in horses.
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